Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
Eli Lilly
Eli Lilly
Page 3 of 7
Retail
Novo Nordisk’s Wegovy sales jump on international rollouts
By
Naomi Kresge
and
Bloomberg
November 6, 2024
Finance
Over 25% of Google’s code is now written by AI—and CEO Sundar Pichai says it’s just the start
By
Greg McKenna
October 30, 2024
Health
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By
Lindsey Leake
October 10, 2024
Health
Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic
By
Christiaan Hetzner
September 25, 2024
Health
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
By
Naomi Kresge
and
Bloomberg
September 12, 2024
Newsletters
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
By
Sheryl Estrada
September 10, 2024
Newsletters
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By
Lydia Belanger
August 5, 2024
Magazine
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
By
Erika Fry
August 2, 2024
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By
Prarthana Prakash
July 29, 2024
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By
Damian Garde
and
Bloomberg
July 11, 2024
Features
Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By
Jessica Mathews
and
Alena Botros
July 9, 2024
Commentary
Alzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By
Anne E. White
July 2, 2024
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By
Amanda Loudin
June 28, 2024
Health
Alzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
By
Matthew Perrone
and
The Associated Press
June 11, 2024
Retail
Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By
Sasha Rogelberg
May 21, 2024
Most Popular
AI
A man let ChatGPT sell his home. It beat every agent's estimate by $100K—and closed in 5 days
By
Jake Angelo
Success
Covid gave us hybrid work. The Iran War might give us a four-day week—and this time, experts say it could stick
By
Orianna Rosa Royle
Real Estate
Gen Z can’t afford a house. Some parents are choosing to fund their down payments over their college funds
By
Jake Angelo